Melanotan II UK - Research Peptides UK Science and Law
Melanotan II UK: Tanning Research, Melanocortin Science, Safety and UK Law
Melanotan II is a synthetic cyclic peptide designed to imitate part of the body’s melanocortin signalling system. Early human experiments showed that it could increase skin pigmentation and trigger sexual effects, but the research programme never produced an authorised Melanotan II medicine. Online tanning, appetite and libido claims now extend far beyond the small and incomplete clinical evidence.
Direct Answer
Melanotan II, also searched as Melanotan 2 or MT2, is a synthetic cyclic heptapeptide related to alpha-melanocyte-stimulating hormone, or alpha-MSH. It activates several melanocortin receptors rather than acting selectively at one target. MC1 receptor activation can increase melanin production in pigment cells. Activity at central melanocortin receptors, particularly MC3 and MC4, is associated with sexual, appetite and autonomic effects.
A pilot phase 1 study in three men reported increased pigmentation in two participants and also recorded nausea, fatigue, yawning, stretching and spontaneous erections. Later small human studies explored erectile responses, but Melanotan II was not developed into an authorised medicine. Appetite and weight-loss claims remain largely based on animal research and pathway inference.
The MHRA stated in 2024 that injectable or pen products containing Melanotan II are classified as medicines in the UK. It also stated that the sale, supply and advertising of unauthorised medicines is not permitted. Nasal products are assessed differently and may be classified according to the claims and overall presentation. No current UK marketing authorisation for Melanotan II was identified when this article was reviewed.
Key Points
What Is Melanotan II?
Melanotan II is a laboratory-designed analogue of alpha-MSH, a naturally occurring melanocortin peptide derived from the larger pro-opiomelanocortin protein. Natural melanocortin signals help regulate pigmentation and also participate in appetite, sexual function, inflammation and autonomic control.
Melanotan II was engineered as a shorter cyclic peptide. The ring structure and use of D-phenylalanine were intended to increase potency and resistance to enzymatic breakdown compared with the natural hormone.
It is not the same as melatonin, the hormone associated with sleep. The similar spelling causes frequent search and labelling confusion.
History and Development
Melanotan II emerged from University of Arizona research into more stable and potent analogues of alpha-MSH.
Analogue Design
Researchers investigated shorter and more stable melanocortin peptides as potential pigmentation agents.
Pilot Phase 1 Study
A three-person study recorded pigmentation alongside nausea, fatigue and spontaneous erectile responses.
Erectile-Response Study
A small double-blind crossover study examined men with psychogenic erectile dysfunction.
Further Human Research
Researchers reported erections in 17 of 20 men without sexual stimulation.
Different Molecules Advanced
Afamelanotide and bremelanotide developed along regulated pathways, while Melanotan II remained unapproved.
Modern internet marketing often combines results from Melanotan II, afamelanotide and bremelanotide as though the names describe interchangeable products. They are related melanocortin analogues, but they have different structures, receptor profiles, formulations and regulatory evidence.
Melanotan II Molecular Profile
The defined research compound is a cyclic seven-residue peptide with an acetylated amino terminus and an amidated carboxyl terminus.
| Common names | Melanotan II, Melanotan 2, MT-II and MT2 |
|---|---|
| Compound type | Synthetic cyclic heptapeptide melanocortin receptor agonist |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
| Molecular formula | C50H69N15O9 |
| Approximate molecular weight | 1,024.18 g/mol |
| CAS number | 121062-08-6 |
| PubChem CID | 92432 |
| Primary pharmacology | Agonist activity at MC1, MC3, MC4 and MC5 receptors |
| Authorised medical use | None identified for Melanotan II |
| UK marketing authorisation | None identified when checked on 21 July 2026 |
Why the Cyclic Structure Matters
Cyclisation constrains the peptide chain and can make a molecule more resistant to enzymatic degradation. It can also alter receptor potency and selectivity. Melanotan II was designed to be more potent than natural alpha-MSH, but broad receptor activity is one reason effects can appear in several biological systems.
The exact ring connection, D-amino-acid configuration and terminal modifications are part of molecular identity. A product labelled “MT2” cannot be authenticated by colour, appearance or a generic purity statement.
Interactive Melanocortin Receptor Explorer
Select a receptor to see the main research context. Human outcomes are not determined by receptor activity alone.
MC1 Receptor
Central to eumelanin production and pigmentation in melanocytes.
MC3 Receptor
Involved in central melanocortin signalling and aspects of energy balance.
MC4 Receptor
Linked with appetite regulation and centrally mediated sexual responses.
MC5 Receptor
Associated with exocrine and immune-related functions.
MC1R and pigmentation
MC1 receptor activation can increase eumelanin synthesis. This explains skin darkening, but it does not make ultraviolet exposure safe or prove protection from skin cancer.
How Is Melanotan II Thought to Work?
Melanotan II is a non-selective melanocortin agonist, so one compound can influence several receptor systems.
Skin Pigmentation
In melanocytes, MC1 receptor signalling increases cyclic AMP and promotes eumelanin production. Increased melanin can darken skin, freckles and existing pigmented lesions.
Sexual Responses
Central MC4 receptor signalling is considered important in Melanotan II’s erectile and sexual effects, although MC3 pathways may also contribute. These effects were observed unexpectedly during early pigmentation research and then studied separately.
Appetite and Energy Balance
MC4 receptor biology is central to appetite regulation. Experimental Melanotan II has reduced food intake in animal models. Human weight-loss efficacy and long-term safety have not been established.
Why Non-Selective Activity Matters
A compound that activates several receptor subtypes may produce a wider range of effects than a selective medicine. Pigmentation, nausea, appetite change, flushing, yawning and sexual effects can arise from overlapping melanocortin pathways.
Melanotan II Human Tanning Research
The direct tanning evidence comes from a very small pilot study rather than a mature clinical programme.
The 1996 Pilot Phase 1 Study
Researchers at the University of Arizona evaluated Melanotan II in three male volunteers. Two participants showed measurable and visually apparent increases in pigmentation after the short study period.
The same study recorded mild nausea at several exposure levels. One participant experienced moderate sleepiness and fatigue. A yawning and stretching complex appeared alongside spontaneous erections that could persist intermittently for hours.
The study established that the molecule could produce biological effects in humans. It did not establish long-term safety, consumer suitability, protection from ultraviolet radiation or an acceptable benefit-risk balance.
Why Three Participants Are Not Enough
A pilot study can reveal biological activity and early tolerability signals. It cannot estimate uncommon risks, compare long-term outcomes, establish cancer safety or support widespread non-medical use.
Melanotan II and Sexual-Function Research
Sexual responses were among the most striking findings of the early human programme.
A small double-blind, placebo-controlled crossover study investigated men with psychogenic erectile dysfunction. Melanotan II initiated erectile responses in a research setting, but nausea and systemic effects complicated the development path.
A later study reported penile erection in 17 of 20 men without sexual stimulation. The average duration of high tip rigidity was approximately 41 minutes. These findings showed a central melanocortin effect, not approval of Melanotan II as an erectile-dysfunction treatment.
Development moved towards bremelanotide, a related cyclic melanocortin agonist with a different terminal structure. Bremelanotide later received US approval for a narrow form of hypoactive sexual desire disorder in certain premenopausal women. That approval belongs to bremelanotide and cannot be transferred to Melanotan II.
Appetite, Weight and Metabolic Research
Appetite claims are scientifically plausible at receptor level but clinically unproven for Melanotan II.
The central melanocortin system is an established regulator of appetite and energy balance. MC4 receptor dysfunction can cause severe hyperphagia and obesity, confirming the biological importance of this pathway.
Melanotan II has reduced food intake and altered feeding behaviour in rodent experiments. These studies help researchers understand melanocortin neurobiology. They do not establish a safe or effective weight-management treatment in humans.
Nausea and reduced appetite should not be reframed automatically as desirable weight-loss benefits. A side effect that reduces eating is not equivalent to durable, healthy or clinically validated weight management.
Evidence at a Glance
Melanotan II has clear receptor activity and limited human proof of pigmentation and sexual effects, but no authorised clinical indication.
| Question | Evidence | Conclusion | Limitation |
|---|---|---|---|
| Does it activate melanocortin receptors? | Receptor pharmacology | Yes | Does not establish clinical safety |
| Can it increase pigmentation? | Three-person pilot study | Biological activity demonstrated | Very small sample |
| Can it trigger erectile responses? | Small controlled studies | Acute responses observed | No authorised Melanotan II indication |
| Does it produce safe weight loss? | Mainly animal evidence | Not established | No mature human programme |
| Does it protect against UV damage? | No reliable protection evidence | Not established | More pigment is not sunscreen |
| Does it cause melanoma? | Case reports | Causation not established | UV exposure confounds reports |
| Is long-term safety known? | Insufficient data | No | Small trials and unregulated supply |
| Is it authorised in the UK? | Official regulatory sources | No authorisation identified | Classification depends partly on presentation |
Melanotan II Does Not Make UV Exposure Safe
A darker appearance must not be confused with complete photoprotection.
Melanin can absorb and scatter some ultraviolet radiation, but induced pigmentation does not replace broad-spectrum sunscreen, protective clothing, shade or avoidance of sunbeds. It also does not remove cumulative DNA damage from ultraviolet exposure.
Some online users combine Melanotan II with sunbeds or deliberate sun exposure to accelerate darkening. This makes risk interpretation difficult because ultraviolet radiation is itself a recognised cause of skin cancer and premature skin ageing.
US regulators previously challenged claims that Melanotan II could reduce skin-cancer risk. No approved evidence supports using it as sunscreen, a skin-cancer preventive treatment or permission for greater UV exposure.
Moles, Pigmented Lesions and Melanoma Uncertainty
The relationship between Melanotan II and melanoma remains uncertain, but changes in pigmented lesions require medical attention.
Published reports describe darkening of existing moles, new pigmented lesions and melanoma diagnosed after Melanotan II exposure. Case reports can raise a safety signal, but they cannot prove that one substance caused a cancer.
Many users also report high ultraviolet exposure or sunbed use. The contributions of Melanotan II, UV exposure, individual susceptibility and product contamination cannot be separated confidently from current evidence.
The FDA’s current compounding-risk information includes melanoma among serious published case reports associated with Melanotan II. This is a warning signal, not a quantified causal risk.
Changing Mole
A mole that changes size, shape, colour or surface should be assessed by a qualified clinician.
No Reliable Risk Percentage
Current evidence cannot provide a trustworthy numerical melanoma risk for Melanotan II users.
Melanotan II Safety and Reported Adverse Events
Controlled safety data are limited, while unregulated products add manufacturing and contamination uncertainty.
Effects Observed in Early Human Research
- Nausea
- Facial flushing
- Fatigue or sleepiness
- Yawning and stretching
- Reduced appetite
- Spontaneous or prolonged erections
- Darkening of freckles and moles
Serious Published Case Reports
The FDA’s April 2026 compounding-risk page states that published case reports involving Melanotan II discuss melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. It also identifies potential immunogenicity concerns from aggregation or peptide-related impurities.
Individual case reports have described systemic toxicity with rhabdomyolysis and renal dysfunction, as well as acute ischaemic priapism requiring urgent treatment. Case reports cannot estimate frequency, but they demonstrate that severe outcomes have been observed.
UK Yellow Card Reports
In an April 2024 Freedom of Information response, the MHRA stated that it had received 16 spontaneous suspected adverse-drug-reaction reports associated with Melanotan II between January 2012 and December 2022.
The MHRA emphasised that a report does not prove causation and that spontaneous reporting is affected by unknown under-reporting. The number should not be used as an incidence rate.
Unregulated Product Risks
- Incorrect peptide identity or sequence
- Wrong cyclic structure or stereochemistry
- Degradation and peptide-related impurities
- Aggregation and possible immunogenicity
- Incorrect net peptide quantity
- Unverified sterility or endotoxin control
- Contamination not declared on the label
- Unreliable nasal-delivery content or absorption
How Laboratories Assess Melanotan II
A meaningful analytical record separates identity, purity, quantity and microbiological claims.
Mass Spectrometry
Tests whether the observed mass is consistent with the expected Melanotan II molecule.
Tandem MS or Mapping
Provides stronger evidence for residue order, D-phenylalanine and terminal modifications.
HPLC or UHPLC
Separates detectable components and estimates relative peak-area purity under a defined method.
Net Peptide Assay
Measures peptide content rather than assuming total powder mass equals active peptide.
Impurity Profiling
Reviews truncations, oxidation, hydrolysis, aggregates and residual synthesis material.
Microbiology and Endotoxin
Require separate validated methods where sterility or endotoxin control is claimed.
What “99% HPLC” Does Not Prove
- That the main peak is Melanotan II
- That the cyclic connection is correct
- That D-phenylalanine has the correct stereochemistry
- The net peptide quantity
- Sterility or absence of endotoxin
- Stability during storage or transport
- Equivalence to early research material
- Suitability for personal use
Melanotan II UK Regulatory Position
Regulatory position checked on 21 July 2026.
No Current UK Marketing Authorisation Identified
No current UK marketing authorisation for Melanotan II was identified in the official medicine-information sources reviewed for this article.
Melanotan II should not be presented as an approved UK tanning, weight-management, sexual-function or skin-protection medicine.
Injectable and Pen Products
In its April 2024 response, the MHRA stated that products containing Melanotan II are classified as medicines if they are injectable or presented in pens. It also stated that the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations.
Nasal Sprays
The MHRA stated that a Melanotan II nasal spray will be determined as a medicine where it is sold with claims to treat or prevent disease. More broadly, classification can depend on composition, pharmacological effect, claims, intended purpose and presentation.
This distinction does not mean that a nasal product is proven safe, high quality or effective. It means the regulatory analysis may differ according to the product’s claims and context.
Research Use Only
A Research Use Only statement does not establish that a product is lawful in every context. Regulators may consider the whole presentation, including tanning promises, appetite claims, sexual-function language, consumer testimonials and instructions aimed at personal use.
MHRA Safety Advice
The MHRA advised people who had used Melanotan II injections or nasal sprays to stop and to speak with a doctor if they experienced side effects, with suspected reactions reportable through the Yellow Card Scheme.
Melanotan II Compared with Related Melanocortin Peptides
Similar ancestry does not make these compounds interchangeable.
| Compound | Profile | Regulated evidence | Authorised use | Key distinction |
|---|---|---|---|---|
| Melanotan II | Non-selective cyclic melanocortin agonist | Small early human studies and case reports | None identified | Broad receptor activity and incomplete safety programme |
| Afamelanotide, formerly Melanotan I | Linear alpha-MSH analogue with strong MC1 activity | Controlled trials and regulated development | Scenesse is authorised for erythropoietic protoporphyria in defined jurisdictions | Prescription implant for a rare disease, not cosmetic tanning |
| Bremelanotide, PT-141 | Related cyclic melanocortin agonist | Large regulated clinical programme | Vyleesi is FDA approved for a narrow form of HSDD in certain premenopausal women | Separate molecule and indication |
| Alpha-MSH | Natural endogenous melanocortin peptide | Extensive physiological research | Not equivalent to Melanotan II as a consumer medicine | Natural hormone with shorter persistence |
Melanotan I vs Melanotan II
Melanotan I is the former development name associated with afamelanotide, a longer linear analogue that became the active ingredient in Scenesse. Melanotan II is a shorter cyclic peptide with broader receptor activity and more prominent central effects.
Melanotan II vs PT-141
Bremelanotide, commonly searched as PT-141, is structurally related to Melanotan II but has a different carboxyl terminus and a separate clinical-development history. FDA approval of Vyleesi does not validate Melanotan II or online PT-141 research products.
Common Melanotan II Claims Examined
Popular claims often combine a genuine biological effect with a conclusion the evidence does not support.
“Melanotan II gives a safe sunless tan.”
Supported: a very small human study showed increased pigmentation.
Not supported: long-term safety, consumer suitability and freedom from UV-related risk.
“A darker tan protects against skin cancer.”
Melanin contributes to natural photoprotection, but Melanotan II has not been proven to prevent skin cancer or replace sunscreen.
“Melanotan II is a weight-loss peptide.”
Melanocortin pathways regulate appetite, but no authorised or adequately tested human weight-management use has been established.
“It is a proven libido treatment.”
Small studies documented erectile responses, but no authorised Melanotan II sexual-health treatment resulted.
“Nasal spray is safer than injection.”
A different route does not establish safety, reliable delivery, purity or long-term evidence.
“A COA proves it is safe.”
A COA may support selected analytical characteristics. It cannot establish clinical safety, cancer risk or approved use.
How to Assess Melanotan II Claims Critically
- Was the cited study actually about Melanotan II?
- Does the page confuse Melanotan II with afamelanotide?
- Does it borrow approval claims from Scenesse or Vyleesi?
- Was the evidence from humans or animals?
- How many people were studied?
- How long did follow-up last?
- Were adverse effects reported clearly?
- Does the source claim tanning prevents UV damage?
- Does it encourage sunbed use?
- Does it describe nausea as a benefit?
- Does it acknowledge priapism and toxicity reports?
- Does the COA match the exact batch?
- Is identity tested separately from purity?
- Is the cyclic structure verified?
- Is net quantity measured?
- Are sterility claims supported?
- Is the product authorised for the claimed purpose?
- Is the source selling the product?
Medical and Editorial Review
This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide transparent authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a professional background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a professional interest in nutritional sciences, dietology, metabolic health and evidence-based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient-centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board-certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence-based aesthetic care.
Read professional profileMelanotan II UK Frequently Asked Questions
Answers to common questions about Melanotan 2, MT2 research, tanning claims, safety and UK law.
What is Melanotan II?
A synthetic cyclic heptapeptide that activates several melanocortin receptors and was originally studied for pigmentation.
Is Melanotan II the same as melatonin?
No. Melatonin relates to sleep timing. Melanotan II is a melanocortin receptor agonist.
What is MT2?
MT2 and MT-II are common abbreviations for Melanotan II.
How many amino acids are in Melanotan II?
It is a cyclic heptapeptide containing seven residues.
How does it affect skin colour?
MC1 receptor activation can stimulate melanocytes to produce more eumelanin.
Has it been studied in humans?
Yes, but the direct human programme was small and did not establish a broad approved treatment.
Is it an approved tanning medicine?
No authorised Melanotan II tanning medicine was identified in the UK or United States.
Is Melanotan II legal in the UK?
The MHRA states that injectable and pen products containing Melanotan II are medicines. Sale, supply and advertising of unauthorised medicines is not permitted. Nasal products may be assessed according to claims and presentation.
Are nasal sprays approved?
No current UK marketing authorisation for a Melanotan II nasal spray was identified.
Does it replace sunscreen?
No. Increased pigmentation does not replace sunscreen, clothing, shade or avoidance of sunbeds.
Does it prevent skin cancer?
No reliable clinical evidence supports using it to prevent skin cancer.
Does it cause melanoma?
Case reports raise concern, but a causal relationship has not been established. UV exposure confounds available reports.
Can it change moles?
Darkening and changes in pigmented lesions have been reported. A changing lesion should be assessed by a clinician.
Can it cause nausea?
Yes. Nausea was reported in early human research.
Can it cause prolonged erections?
Yes. Early studies and case reports describe prolonged erections and priapism.
Does it reduce appetite?
Reduced appetite is plausible through melanocortin pathways, but it is not an established safe weight-loss treatment.
Is it the same as Melanotan I?
No. Melanotan I is associated with afamelanotide, a different linear peptide used in a regulated prescription implant.
Is it the same as PT-141?
No. PT-141 is bremelanotide, a related but distinct molecule.
Does 99% HPLC prove identity?
No. HPLC purity alone does not prove identity, correct cyclisation, stereochemistry, quantity, sterility or safety.
What does Research Use Only mean?
It describes an intended laboratory purpose. It does not prove authorisation, quality, safety or universal legal compliance.
Why is there no tanning protocol here?
Melanotan II is not an authorised UK tanning medicine, and this article does not provide personal-use instructions.
Key Takeaways
- Melanotan II is a cyclic alpha-MSH analogue with activity at several melanocortin receptors.
- A three-person pilot study showed pigmentation but also nausea, fatigue and erectile effects.
- Small human studies confirmed erectile responses, but no authorised Melanotan II medicine resulted.
- Weight-loss claims rely mainly on animal research and pathway inference.
- It does not replace sunscreen or make sunbeds safe.
- Case reports raise concerns about priapism, systemic toxicity and pigmented lesions.
- A causal link with melanoma is not established, but long-term reassurance is also unavailable.
- The MHRA classifies injectable and pen products containing Melanotan II as medicines.
- No current UK marketing authorisation was identified.
- Analytical purity does not establish clinical safety.
Relevant It’s Me & You Clinic Resources
Research Peptides UK
Browse the wider peptide research, testing and UK law series.
Browse the seriesGHK-Cu UK
Compare Melanotan II with a different skin-related peptide research field.
Read the guideReferences
- Dorr RT, et al. Evaluation of Melanotan-II in a pilot phase I clinical study. Life Sciences. 1996. PubMed
- Wessells H, et al. Human studies with Melanotan II. International Journal of Impotence Research. 2000. PubMed
- PubChem. Melanotan II, CID 92432. PubChem
- Yeo GSH, et al. The melanocortin pathway and energy homeostasis. 2021. PMC
- US FDA. Bulk substances that may present significant safety risks. Updated 22 April 2026. FDA
- MHRA. FOI 24/274, Melanotan II products. 17 April 2024. MHRA
- MHRA. Borderline products guidance. Updated 2 July 2026. GOV.UK
- Nelson ME, et al. Melanotan II systemic toxicity and rhabdomyolysis. 2012. PubMed
- Mallory CW, et al. Melanotan tanning injection and priapism. 2021. PubMed
- Hjuler KF, Lorentzen HF. Melanoma associated with Melanotan II use. 2014. PubMed
- EMA. Scenesse, afamelanotide. EMA
- US FDA. Vyleesi, bremelanotide label. FDA label
- Cancer Research UK. Tanning, fake tan and Melanotan. Cancer Research UK
- UKAS. Laboratory accreditation and ISO/IEC 17025 scope. UKAS
